US.AMGN · Amgen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.0155893362549073,
        "turnoverUsdM": 1031.3081928,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.AMGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 420.4586,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4,
      "take_profit_price": 460.026,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.240332023508895,
    "stopLossPercent": 4.031178672509815,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 62.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 426.4135,
    "ma50": 391.6026,
    "close": 438.12,
    "prevClose": 429.88,
    "avgVolume20": 2457157,
    "volumeRatio": 0.96,
    "changePercent": 1.92
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.009316185992135129,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.9338826745272446,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.7212995558612986,
      "volat_points": 0,
      "day_range_pct": 0.01746094677257373,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 62.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 17.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.33,
        "contribution": 17.5
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 58.9,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 17.5/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 13.2,
      "市場環境": 8,
      "情緒分析": 6,
      "技術信號": 17.5,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0.6,
          "turnoverUsdM": 1031.3081928,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 3.2,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.AMGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 717.9660035,
                "ma50": 710.9806006399998,
                "name": "QQQ",
                "close": 707.64001,
                "points": 0.4
              },
              "spy": {
                "ma20": 769.2074954000002,
                "ma50": 754.7092016199999,
                "name": "SPY",
                "close": 761.78003,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.0155893362549073,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 0,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 5,
              "sentimentScoreRaw": 1.5
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141333843,
                "url": "https://finnhub.io/api/news?id=8a8c5b876fa5e2cee1a133c4db80a27994d4d0e6fcd1b348c3178f93e13b8b1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.",
                "category": "company",
                "datetime": 1787846220,
                "headline": "AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study"
              },
              {
                "id": 141361446,
                "url": "https://finnhub.io/api/news?id=455a9118e9ec22632d4614e4c560565c3bd632db12cd6527e3c3f8f3881ddc26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...",
                "category": "company",
                "datetime": 1787774930,
                "headline": "Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?"
              },
              {
                "id": 141278698,
                "url": "https://finnhub.io/api/news?id=4394f6ad9715a6c94291783df5d3fa55f73a753e76fd10b22ca5b268c5fd81ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Analyst reaction to Amgen’s latest quarter Amgen (AMGN) is back in focus after Argus raised its price target to $460 from $375 while maintaining a Buy rating, following second quarter results and reported progress across the company’s drug portfolio. See our latest analysis for Amgen. Beyond the latest quarter, Amgen’s recent news sits against strong momentum in the stock, with a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%. This points to building...",
                "category": "company",
                "datetime": 1787317776,
                "headline": "Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?"
              },
              {
                "id": 141200935,
                "url": "https://finnhub.io/api/news?id=21bbf513dbd9172d14a0db0c2ada1abdc81e2758c6fe6dc5a9e5557ecdee1cc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Revenue surged 10% as six growth drivers now fuel 70% of product sales.",
                "category": "company",
                "datetime": 1786492676,
                "headline": "Amgen (AMGN) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141159833,
                "url": "https://finnhub.io/api/news?id=f01a58be3d06aa00897a152bfa56512d484414e34861a87c5ee358869e0f6566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...",
                "category": "company",
                "datetime": 1786209194,
                "headline": "Amgen (AMGN) Stock Sees Fair Value Lift After Q2 Beat And Analyst Target Hikes"
              },
              {
                "id": 141124169,
                "url": "https://finnhub.io/api/news?id=72c45d59d23cf8a80168bb098a63031a9d5d3b7a5025fb2a8250cc243fa24256",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.",
                "category": "company",
                "datetime": 1785945300,
                "headline": "AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure"
              },
              {
                "id": 141122570,
                "url": "https://finnhub.io/api/news?id=8a9aed862fe00626b74388d7bd0bfa8f3652bc96e8189f67de8571e5e82f2ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.",
                "category": "company",
                "datetime": 1785938400,
                "headline": "AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline"
              },
              {
                "id": 141119257,
                "url": "https://finnhub.io/api/news?id=c78686d056d119c01052d5be3c5a7c135531134c085fa378985c867a2e7bd6fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "How Amgen’s latest earnings event sets the stage for investors Amgen (AMGN) just released its second quarter 2026 results, reporting revenue of US$10.05b and net income of US$2.38b, alongside updated full year guidance that gives investors fresh numbers to work with. For the first half of 2026, Amgen reported revenue of US$18.67b and net income of US$4.19b. Basic earnings per share from continuing operations were US$7.77, with diluted EPS at US$7.71 for the period. The company now expects...",
                "category": "company",
                "datetime": 1785913989,
                "headline": "Amgen (AMGN) Lifted 2026 Guidance, Is The Valuation Still Too Rich?"
              }
            ],
            "raw_source": [
              {
                "id": 141370623,
                "url": "https://finnhub.io/api/news?id=2811d09bc453d60ad535201a16e94c17326b4e0711eab591a46c0c53c4effcac",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788289805,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 141368965,
                "url": "https://finnhub.io/api/news?id=c80d53f7cac54342cabbb62192f561e4ee503d10c3a9000331444aeb6824eebf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1788280806,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 141360811,
                "url": "https://finnhub.io/api/news?id=a1f104c3eed67391ce32d2481aac2b51ac1441afa4355422bc7afdfdddc7f243",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.",
                "category": "company",
                "datetime": 1788270346,
                "headline": "Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs"
              },
              {
                "id": 141361447,
                "url": "https://finnhub.io/api/news?id=ab07afbee46f4905a98a9ba2afbf0f2b2614468625b04d7c77ceebad8bf6ba51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches. “Eric is an exceptional biopharmaceutical leader w",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer"
              },
              {
                "id": 141361434,
                "url": "https://finnhub.io/api/news?id=29911028cc6b0101125f19b0bbcb6c5df63ce42e0d3d0038a3a23bd5dea19de7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.",
                "category": "company",
                "datetime": 1788211269,
                "headline": "One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%"
              },
              {
                "id": 141360940,
                "url": "https://finnhub.io/api/news?id=036a665dfcf2073c36a6a6f575341e937f13f43edd6e086929670ab6bb25ecb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.",
                "category": "company",
                "datetime": 1788193740,
                "headline": "Aging Population Drives Healthcare Growth: Stocks to Watch"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141361435,
                "url": "https://finnhub.io/api/news?id=7d9984be8ef9f71808fa1ef70118ae522b6a82d2417130e69e42a031408e3888",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.",
                "category": "company",
                "datetime": 1788179627,
                "headline": "How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361448,
                "url": "https://finnhub.io/api/news?id=247b5f6fb2e792b2b976e2e3c0a3d8dea41e34ecf81ad68e0b96cdb61a1bc71e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035"
              },
              {
                "id": 141360873,
                "url": "https://finnhub.io/api/news?id=6b7828153da95e7d98471f4497d58e848236a54aadd439f193674200df7e7991",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel"
              },
              {
                "id": 141355786,
                "url": "https://finnhub.io/api/news?id=a04bfac45540e9679c9cab472d6a6223d4fabda8d0218940450e94b4089fdeda",
                "image": "https://image.cnbcfm.com/api/v1/image/108356386-17881846431788184641-48095170488-1080pnbcnews.jpg?v=1788184642&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.",
                "category": "company",
                "datetime": 1788170354,
                "headline": "Cramer’s Stop Trading: Amgen"
              },
              {
                "id": 141361437,
                "url": "https://finnhub.io/api/news?id=b783deb23312421a2f43e59397b9eea7d682b047b14e2e188c6dab9538d65345",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments. The results are from a pre-specified analysis of the Phase 3 VESALIUS-CV trial and were presented in a late-breaking science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. They were also simultaneousl",
                "category": "company",
                "datetime": 1788164280,
                "headline": "AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE"
              },
              {
                "id": 141357518,
                "url": "https://finnhub.io/api/news?id=3cc99eb6a73d19db79ea9a3e1c7e751913fd6a9eeeff2e40c4ebdb85f18a3188",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein",
                "category": "company",
                "datetime": 1788148711,
                "headline": "Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients"
              },
              {
                "id": 141361438,
                "url": "https://finnhub.io/api/news?id=940a43f5ddc818d2bd608a743ecdb586ed6fb5e91ade75734e7d1edb77b505aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.",
                "category": "company",
                "datetime": 1788023101,
                "headline": "Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141339387,
                "url": "https://finnhub.io/api/news?id=5b27de5152d79b81f60ff69ee0c2f519f474646bac52a822fe2fd7513d0b0db2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the dow jones index performance on Friday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1787944206,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141338491,
                "url": "https://finnhub.io/api/news?id=55cae651cbeff84fbf63cc5a69133b5bb10f6b6420ada6c314a3e1af3a9e0019",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787935206,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141351854,
                "url": "https://finnhub.io/api/news?id=0e0d980591782fc5a3c1078af4ef77582645ce33e3a8a7c0cf8f68d55b5a61b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...",
                "category": "company",
                "datetime": 1787897307,
                "headline": "AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?"
              },
              {
                "id": 141348579,
                "url": "https://finnhub.io/api/news?id=d17b53e42200b5ccd779b54e678ee75e7575b5645e80bad7013e99a7f2c183ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1787879989,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141351856,
                "url": "https://finnhub.io/api/news?id=f4bb0891bf60431695c3e21ae502bfb3cdd9965ddaacac579d244f8058de09a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.",
                "category": "company",
                "datetime": 1787866152,
                "headline": "Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?"
              },
              {
                "id": 141351857,
                "url": "https://finnhub.io/api/news?id=be352f546f35f9a6feeacf135e1a4b2a7d198f8c66be512a1fe9d57aa32cc3e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Tezspire met both primary endpoints in an esophagitis trial, but AstraZeneca shares slipped roughly 0.6% Thursday.",
                "category": "company",
                "datetime": 1787861438,
                "headline": "AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141333843,
                "url": "https://finnhub.io/api/news?id=8a8c5b876fa5e2cee1a133c4db80a27994d4d0e6fcd1b348c3178f93e13b8b1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.",
                "category": "company",
                "datetime": 1787846220,
                "headline": "AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study"
              },
              {
                "id": 141361452,
                "url": "https://finnhub.io/api/news?id=707ffe934c235d0ef12b23c7db0c1acee3ac3f9b29eae283b45ead7a8f12d05b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1787839507,
                "headline": "1 Unpopular Stock That Should Get More Attention and 2 We Find Risky"
              },
              {
                "id": 141331717,
                "url": "https://finnhub.io/api/news?id=b76b2b2c443ab9cdc5e0d7b1f80faa2c059934c65cbfad7ab85c3c4e47c4c2d8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787837726,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141351858,
                "url": "https://finnhub.io/api/news?id=a697d51ed3ac7cee7fcbfb48d5614c86182abb7fe9132af0def549b5775ef0a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.",
                "category": "company",
                "datetime": 1787835480,
                "headline": "New data could widen use of AstraZeneca, Amgen immune disease drug"
              },
              {
                "id": 141351862,
                "url": "https://finnhub.io/api/news?id=a55c11406851f9f0df8a800dd41e263f9069ffa35cbf47b2c0824658019bf8d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "If approved in EoE, Tezspire will notch another indication onto its belt – adding to its legacy defined by approvals in asthma and CRSwNP.",
                "category": "company",
                "datetime": 1787833814,
                "headline": "Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win"
              },
              {
                "id": 141361444,
                "url": "https://finnhub.io/api/news?id=7fce77662026ee56a6a85e89624d80aff4a749db83b86f1dd778acfe63dec621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Global KIF18A Targeting Therapies Clinical Innovation, Combination Treatment Strategies, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026\" has been added to ResearchAndMarkets.com's offering. The latest Global KIF18A-Targeting Therapies Clinical Innovation and Clinical Trials Insight 2026 Report provides a comprehensive assessment of the emerging KIF18A inhibitor landscape, including clinical development programs, combinat",
                "category": "company",
                "datetime": 1787826000,
                "headline": "Global KIF18A Targeting Therapies Market Insights Report 2026: Profiles Volastra, Accent, Insilico, Amgen, Aurigene, Tailor Bio and Other Key Players"
              },
              {
                "id": 141330520,
                "url": "https://finnhub.io/api/news?id=f8bc6c1e27b6d5b2830aadcba05a890393bd2e414901ceca49fa20768f603628",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.",
                "category": "company",
                "datetime": 1787817722,
                "headline": "AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease"
              },
              {
                "id": 141330521,
                "url": "https://finnhub.io/api/news?id=754c68db26ba8c7f65d9f5aeb30e6b1de642b38fa9e70438e37b6bcc3308da06",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52Efficacy in a third epithelial-driven inflammatory disease supports broad potential of",
                "category": "company",
                "datetime": 1787814356,
                "headline": "AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial"
              },
              {
                "id": 141351863,
                "url": "https://finnhub.io/api/news?id=26ebf53de81fbf0bcac87cb6887953ed30fc5a76fd6b160680e6d9db99ffc304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE). TEZSPIRE demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing).",
                "category": "company",
                "datetime": 1787814000,
                "headline": "TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS"
              },
              {
                "id": 141330522,
                "url": "https://finnhub.io/api/news?id=13b90c42b14cef14d5b577c3f28564e3d7ec832e6286b903122e9842d8e8724f",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of",
                "category": "company",
                "datetime": 1787797487,
                "headline": "Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis"
              },
              {
                "id": 141361446,
                "url": "https://finnhub.io/api/news?id=455a9118e9ec22632d4614e4c560565c3bd632db12cd6527e3c3f8f3881ddc26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other...",
                "category": "company",
                "datetime": 1787774930,
                "headline": "Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?"
              },
              {
                "id": 141322441,
                "url": "https://finnhub.io/api/news?id=ea4ad1157b42d6bad453f53df9599e9e64e5dddcb48416e8ed75336323562ec6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177662436/image_2177662436.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "STK yields 3.56% with special distribution potential, while SCHD's 2.98% yield reflects strong price appreciation. Check out the strategy with SCHD and STK here.",
                "category": "company",
                "datetime": 1787731200,
                "headline": "SCHD And STK: A 3%+ Income Barbell"
              },
              {
                "id": 141324524,
                "url": "https://finnhub.io/api/news?id=d49de4226effdbafe004801a69a0e0b74bb2c754a1fb879e22040e27f9bd5282",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 14.92%. Currently, Amgen has a market capitalization of $241.16 billion.",
                "category": "company",
                "datetime": 1787659259,
                "headline": "Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years"
              },
              {
                "id": 141316212,
                "url": "https://finnhub.io/api/news?id=5e6fefaa99fcd424019f11ce4f04ca63d98863c1cd874b1f5971c0ae40aed934",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230550003/image_2230550003.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.",
                "category": "company",
                "datetime": 1787648487,
                "headline": "Regeneron: Why I Still See Upside After The Rally"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141278712,
                "url": "https://finnhub.io/api/news?id=63de56b64fc03c6b060027a391c49efa3d653026a1804b3f9dcd06f4a464d73c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Suddenly the Nasdaq couldn’t hold onto early gains, and you can probably guess which stocks are to blame.  The Nasdaq Composite was hovering around breakeven after a wave of selling hit chips and AI infrastructure stocks.  The S&P 500 was still up 0.3%.",
                "category": "company",
                "datetime": 1787326179,
                "headline": "Why the Dow Is Beating the Nasdaq Again"
              },
              {
                "id": 141278704,
                "url": "https://finnhub.io/api/news?id=22892713c976d04ea1571779ad51eaf32a02a67173f8e9b9bd0bca16a08af077",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development.",
                "category": "company",
                "datetime": 1787326126,
                "headline": "Making Drugs With AI: Biopharma Giants Gear Up For New Arena"
              },
              {
                "id": 141278698,
                "url": "https://finnhub.io/api/news?id=4394f6ad9715a6c94291783df5d3fa55f73a753e76fd10b22ca5b268c5fd81ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Analyst reaction to Amgen’s latest quarter Amgen (AMGN) is back in focus after Argus raised its price target to $460 from $375 while maintaining a Buy rating, following second quarter results and reported progress across the company’s drug portfolio. See our latest analysis for Amgen. Beyond the latest quarter, Amgen’s recent news sits against strong momentum in the stock, with a 30 day share price return of 18.49% and a 1 year total shareholder return of 51.76%. This points to building...",
                "category": "company",
                "datetime": 1787317776,
                "headline": "Amgen (AMGN) Gets A Fresh Target, Is It Fully Priced?"
              },
              {
                "id": 141270540,
                "url": "https://finnhub.io/api/news?id=116c11c87c38da79036c16efcd11562a853d9083eec117f66078dbf626d0cc71",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229006239/image_2229006239.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costly—and what to do now.",
                "category": "company",
                "datetime": 1787311688,
                "headline": "SCHD: We Were Horribly Wrong"
              },
              {
                "id": 141263725,
                "url": "https://finnhub.io/api/news?id=dfd1ab1771431dd4977c3660606f49ee58f6377693bed6cc3754ed3555c67ed0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Thursday.",
                "category": "company",
                "datetime": 1787253006,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 141262494,
                "url": "https://finnhub.io/api/news?id=1d8363aabcf751eaf84d1590e0e4b66548c336e4febf069797c0fb58279fa25d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1787244004,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 141275701,
                "url": "https://finnhub.io/api/news?id=1bd3711c12775f44bfe4b1cffe65adc214e915d7f46bacefa634e8420b121dab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The \"Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030\" has been added to ResearchAndMarkets.com's offering. Key Report Highlights: Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030Analysis of current market trends, growth drivers and future commercial opportunitiesUnited States expected to dominate market sales, wh",
                "category": "company",
                "datetime": 1787243400,
                "headline": "Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics"
              },
              {
                "id": 141263709,
                "url": "https://finnhub.io/api/news?id=1b9fd2d62d8e037c8e8f717a02474c4bab6edf4a4f09fe12b87288303fce6f82",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Piper Sandler  analyst David Amsellem   maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $427 to $457.",
                "category": "company",
                "datetime": 1787228691,
                "headline": "Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457"
              },
              {
                "id": 141278705,
                "url": "https://finnhub.io/api/news?id=69cb7de54e7da761a80eac0f0133507400fc44f419b7fb28eaf8e2626d676e07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.",
                "category": "company",
                "datetime": 1787220915,
                "headline": "2 Momentum  Stocks Worth Investigating and 1 We Avoid"
              },
              {
                "id": 141278699,
                "url": "https://finnhub.io/api/news?id=c435b285f97386e40fc3d9bc122e86667f275d02e2db96f78c442dbfe706b4a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.",
                "category": "company",
                "datetime": 1787170816,
                "headline": "Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?"
              },
              {
                "id": 141278700,
                "url": "https://finnhub.io/api/news?id=985d0e1d47d0d5fe101a6ed97587da04d00c591e0825cf14528c72e9092d8e5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Both Amgen and Repligen saw price target hikes after better-than-expected Q2 results and potential gains from Moderna’s successful Phase 3 trial for melanoma therapy, respectively.",
                "category": "company",
                "datetime": 1787167260,
                "headline": "These Two Biotech Stocks Recorded Fresh Milestones Today – What’s Driving Today’s Gains?"
              },
              {
                "id": 141255654,
                "url": "https://finnhub.io/api/news?id=40115c3c3464e83a2660ead2dc4dec4295ca940e8503f339c0e49581f3b5cef4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1787166605,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 141278701,
                "url": "https://finnhub.io/api/news?id=d47c5497e6829d92299a7a2cc7908dc9d55d7c11e63e91a718228e14948319a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.",
                "category": "company",
                "datetime": 1787164205,
                "headline": "Amgen Stock Surges 3.5% as Healthcare Hits Record High"
              },
              {
                "id": 141278706,
                "url": "https://finnhub.io/api/news?id=86afab7b009e37be074eae9ef98e45d9276485f1f2d5365a1e19f1f2070e2ce0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Ben Zercher is senior analyst of biotech and pharma at PitchBook Obesity drugs offered the holy grail of drug development: a massive market, biology that works, and a proven blueprint paved by blockbuster GLP-1s. But the gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stag",
                "category": "company",
                "datetime": 1787135040,
                "headline": "Obesity investing’s way forward, mapped"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141253952,
                "url": "https://finnhub.io/api/news?id=2afae83d45198e3ee1a982126a207dda65d46012649e8de405588bec034eab7c",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Argus Research  analyst Jasper Hellweg   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $375 to $460.",
                "category": "company",
                "datetime": 1787131035,
                "headline": "Argus Research Maintains Buy on Amgen, Raises Price Target to $460"
              },
              {
                "id": 141247856,
                "url": "https://finnhub.io/api/news?id=93ae485a341815fe23fcf7ff4561ae7f48c8b2dacec60a5793cc677ac3351659",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787080206,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141249352,
                "url": "https://finnhub.io/api/news?id=1011302742ecb6c729b832b6fcd1571d9373383ba3f323443bed1b8b593db274",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,",
                "category": "company",
                "datetime": 1787072932,
                "headline": "Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026"
              },
              {
                "id": 141246754,
                "url": "https://finnhub.io/api/news?id=c403cfdc8e76b95c2c482fae3fa9b3d407ffa166cf0ae935a0f4797898d64f03",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1787071206,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 141278192,
                "url": "https://finnhub.io/api/news?id=c16a4fc0b4883ced1e09a9b7c881e88177284270c9e703188f98c2fc2d2d929d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.",
                "category": "company",
                "datetime": 1787065823,
                "headline": "Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore"
              },
              {
                "id": 141247734,
                "url": "https://finnhub.io/api/news?id=a607edaa23bb540143fdfe73de9dde5d38de54822e9469632d272690e461761a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787060120,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141246035,
                "url": "https://finnhub.io/api/news?id=e298aa77f53039ad1b7b9536c01d64d1abd4da5750dd352bbe9f946d6d547061",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/18/Nassau--Bahamas---April-16--2008-The-Nor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co raised the price target for argenx SE - ADR (NASDAQ: ARGX) from $940 to $1,202. Goldman Sachs boosted PBF Energy Inc (NYSE: PBF) price target from $71 to $81. B of A Securities increased price target for Americold Realty Trust Inc (NYSE: COLD) from $15 to $16.",
                "category": "company",
                "datetime": 1787041565,
                "headline": "Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday"
              },
              {
                "id": 141275702,
                "url": "https://finnhub.io/api/news?id=dd1ad631c87733fc3297a6c3232ebe953f9c2a30eb27e40eb66a8c38d5c3ac84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Prista Charuworn, MD, as Chief Medical Officer. Dr. Charuworn completed fellowships in gastroenterology and transplant hepatology at Stanford and has extensive",
                "category": "company",
                "datetime": 1787040000,
                "headline": "Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer"
              },
              {
                "id": 141246633,
                "url": "https://finnhub.io/api/news?id=2a087cc3900171a472633fa33c452684082eb42001826f9065e18f976fa29edb",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Mizuho  analyst Salim Syed   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $303 to $352.",
                "category": "company",
                "datetime": 1787039581,
                "headline": "Mizuho Maintains Neutral on Amgen, Raises Price Target to $352"
              },
              {
                "id": 141246634,
                "url": "https://finnhub.io/api/news?id=56d3d499d9b0a1773f56f0e920a4865ec0ee9116cbad04cacdc7d434413e9f30",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $350 to $400.",
                "category": "company",
                "datetime": 1787036302,
                "headline": "Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $400"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141278709,
                "url": "https://finnhub.io/api/news?id=9fcf68c0fbb3d26db8e83234ee637051d2d45d5fb337aa6891f5c549a65cd778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.",
                "category": "company",
                "datetime": 1787005778,
                "headline": "Why Isn't Eli Lilly Stock Trading At The Top Of Its Peer Group?"
              },
              {
                "id": 141266872,
                "url": "https://finnhub.io/api/news?id=15f5bf0ab6810b43d8e36ceb1b2cc68f72f1a1364866d6566dee979acdc57c18",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "This top dividend ETF is still a reliable long-term income investment.",
                "category": "company",
                "datetime": 1786998933,
                "headline": "If You Invest $100 a Month in SCHD, Here's the Passive Income It Could Deliver in 20 Years"
              },
              {
                "id": 141242298,
                "url": "https://finnhub.io/api/news?id=6c674bf3153c4c112b1c368a5a3d8d5c53ce0cb6ca09bafc6aeb63dd260d5f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2062658519/image_2062658519.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "SCHD is beating SPY amid volatility—see top-performing, undervalued dividend stocks, YTD leaders, and 10%+ upside potential.",
                "category": "company",
                "datetime": 1786996527,
                "headline": "The Hidden Winners Inside SCHD - August 2026"
              },
              {
                "id": 141240002,
                "url": "https://finnhub.io/api/news?id=ec0668889a4c1c71892f8037054930e2b4ad337fa2c786bae0c8ac483da2e41c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786993806,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 141278711,
                "url": "https://finnhub.io/api/news?id=ae3e5f6ba263448cd46f415692f71404e4f9e76af635fb62fbccf76521cca40f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker “SLTE.” Slate reported it secured an oversubscribed concurrent private placement of $245 […] The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on Exec",
                "category": "company",
                "datetime": 1786986673,
                "headline": "Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies"
              },
              {
                "id": 141238736,
                "url": "https://finnhub.io/api/news?id=b91ca1b80516fc75a10e9df868b364cf20cf41b442449092f5176ac5b0392a13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1786984806,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141224230,
                "url": "https://finnhub.io/api/news?id=378bd32677ead84815eb5c03e6e3830b56b7b1e398114ef6ed1b456b3a5bcb95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503342678/image_1503342678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "A SWAN income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning. Read how to build one here.",
                "category": "company",
                "datetime": 1786781400,
                "headline": "How To Invest $100,000 In A Retiree's SWAN Income Portfolio"
              },
              {
                "id": 141220362,
                "url": "https://finnhub.io/api/news?id=aca754d054c2cc29e122e29d60fc10d0d806a9a9424655c9d9e085ef4de25d34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Weekly dividend summary for Dividend Champions, Contenders & Challengers—read the full list of dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786730477,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 16"
              },
              {
                "id": 141217398,
                "url": "https://finnhub.io/api/news?id=9aa0c7405fb35fba6c170c4b0e6fb0522d03435cb57c024ebca3a1d82648d3f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786725606,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141219196,
                "url": "https://finnhub.io/api/news?id=d589796c49ee8c58aad29f907397207bc3d2821e4436174cdabb2cfa8eb12a60",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1786714524,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141228124,
                "url": "https://finnhub.io/api/news?id=224eb5046870aacd7c7b85156f2ed660e399c2b31c5295e9b344e025af735a5c",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Barclays  analyst Emily Field   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $360 to $380.",
                "category": "company",
                "datetime": 1786702679,
                "headline": "Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380"
              },
              {
                "id": 141210911,
                "url": "https://finnhub.io/api/news?id=427d96ba73e5736bcfc30b54d9aa8ec19d41903433d425e3fe26cae063c3087f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.",
                "category": "company",
                "datetime": 1786652069,
                "headline": "How to Build $7,200 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141205461,
                "url": "https://finnhub.io/api/news?id=3e8c6b5b588b6fb76f2d072ee68087552deaa82564a5299a0a7abda6956937fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.",
                "category": "company",
                "datetime": 1786626308,
                "headline": "Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover"
              },
              {
                "id": 141204156,
                "url": "https://finnhub.io/api/news?id=fbb368ddcc1c7bb3906d4917505a08f91421cbb48c0976e0175cae20d9e709ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company’s outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, “Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow",
                "category": "company",
                "datetime": 1786608300,
                "headline": "Amgen’s Q2 Earnings Call: Our Top 5 Analyst Questions"
              },
              {
                "id": 141200938,
                "url": "https://finnhub.io/api/news?id=b35b99983b6997570e646c154eb2a95de73ff315d9b0ae9d33c8553a03459530",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.",
                "category": "company",
                "datetime": 1786583098,
                "headline": "BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ..."
              },
              {
                "id": 141206330,
                "url": "https://finnhub.io/api/news?id=b48a49126c69ae7754badde85bb6d7fde33ff1c2762086ba9e2bc250215c8ab7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/3d-Rendering-Of-A-Red-Medical-Capsule-An.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "China’s science surge is reshaping global drug development as Washington moves to counter Beijing’s growing influence in medicine.",
                "category": "company",
                "datetime": 1786574462,
                "headline": "Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141195031,
                "url": "https://finnhub.io/api/news?id=78e6af217bf3b8ef504efd01eebe1e228efe4df12fa1c3ac18a373b2e6fb651e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.",
                "category": "company",
                "datetime": 1786561805,
                "headline": "Wednesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141200934,
                "url": "https://finnhub.io/api/news?id=51423c6396c421237722e1907ce3fc5714bac9b2cada2e319c7e3b72f186a01a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen's global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities.",
                "category": "company",
                "datetime": 1786523100,
                "headline": "AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD"
              },
              {
                "id": 141196283,
                "url": "https://finnhub.io/api/news?id=bccd923da82b5927dd871d78e7a649189f06fed04fada2c3503e7af9c9771763",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "The center will join Amgen's global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities. The new site reflects",
                "category": "company",
                "datetime": 1786515691,
                "headline": "Reported Earlier, Amgen To Open New Science And Innovation Center At Genome Valley In Hyderabad"
              },
              {
                "id": 141200935,
                "url": "https://finnhub.io/api/news?id=21bbf513dbd9172d14a0db0c2ada1abdc81e2758c6fe6dc5a9e5557ecdee1cc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Revenue surged 10% as six growth drivers now fuel 70% of product sales.",
                "category": "company",
                "datetime": 1786492676,
                "headline": "Amgen (AMGN) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141200559,
                "url": "https://finnhub.io/api/news?id=feaf31990ebe1ceb523c5f1b9d691ebafed30db00bd3a3adceb561b1762a6ccc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Three household names are days away from their ex-dividend dates, and missing the cutoff by even one session means that specific cash payment goes to someone else. The clock is running on MSFT, AMGN, and MAR.",
                "category": "company",
                "datetime": 1786471006,
                "headline": "Dividend Stocks That Are Paying Investors Cash"
              },
              {
                "id": 141199701,
                "url": "https://finnhub.io/api/news?id=b50e0c3beda411a326fc6693d3316dd514cc3e1ea7e876b0839c0435b99660a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by letting someone else snap it up first?",
                "category": "company",
                "datetime": 1786454439,
                "headline": "A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?"
              },
              {
                "id": 141185972,
                "url": "https://finnhub.io/api/news?id=a4d51d88a748a451808eab1e5982cbf95cebcbfe8d81ebb09293098438708c11",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized basis producing an average annual return of 14.88%. Currently, Amgen has a market capitalization of $223.91 billion.",
                "category": "company",
                "datetime": 1786449622,
                "headline": "$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141179899,
                "url": "https://finnhub.io/api/news?id=7ceda054cbf1a9731f12135ecf892bed93b994a2553ae0995829b82575cad1ad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2233342016/image_2233342016.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.",
                "category": "company",
                "datetime": 1786389747,
                "headline": "Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News"
              },
              {
                "id": 141177337,
                "url": "https://finnhub.io/api/news?id=2f75049ab7be9065daa72677147eb7c5f80eb38c8674a895383a372bc4e3f887",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1786389005,
                "headline": "Stay informed with the top movers within the dow jones index on Monday."
              },
              {
                "id": 141177536,
                "url": "https://finnhub.io/api/news?id=06f9855d2799e576a4ddc346eaf2e110f1bc1ef8bcee92747cb4ca2cb44668bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]",
                "category": "company",
                "datetime": 1786385250,
                "headline": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY"
              },
              {
                "id": 141176537,
                "url": "https://finnhub.io/api/news?id=3095480400af9b48e867b36c70234450d3fa5550b19fa7fb2d393ea7285a780c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.",
                "category": "company",
                "datetime": 1786381214,
                "headline": "The “Set It & Forget It” Stocks I’d Want to Own"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141174790,
                "url": "https://finnhub.io/api/news?id=60a9a79aa089eb5e9afc933632c55786dea91f6b58129376974cbbca45c8b823",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $343 to $388.",
                "category": "company",
                "datetime": 1786355007,
                "headline": "Guggenheim Maintains Neutral on Amgen, Raises Price Target to $388"
              },
              {
                "id": 141174082,
                "url": "https://finnhub.io/api/news?id=e6ce91f5af34345df55033a4670541763ba669f9aa3ee976e2788077cf1ed33a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/897600234/image_897600234.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Gilead’s 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.",
                "category": "company",
                "datetime": 1786353380,
                "headline": "Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)"
              },
              {
                "id": 141171514,
                "url": "https://finnhub.io/api/news?id=f35751192ac9ff5de0fe1ad8b86e96f8dff627bca8ed6b2c5e4a01d872cb07d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.",
                "category": "company",
                "datetime": 1786332858,
                "headline": "How to Build $13,000 a Month in Dividend Income From Three Income Buckets"
              },
              {
                "id": 141159833,
                "url": "https://finnhub.io/api/news?id=f01a58be3d06aa00897a152bfa56512d484414e34861a87c5ee358869e0f6566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...",
                "category": "company",
                "datetime": 1786209194,
                "headline": "Amgen (AMGN) Stock Sees Fair Value Lift After Q2 Beat And Analyst Target Hikes"
              },
              {
                "id": 141155564,
                "url": "https://finnhub.io/api/news?id=5cd1e43eec17114a328d7441137425546e16443c9dd2c02c7f813504f2b02ba3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The yield you chase at 52 could quietly cannibalize the very nest egg you need at 62. Before you reach for the biggest monthly payout, understand the compounding trap hiding inside each income tier.",
                "category": "company",
                "datetime": 1786154776,
                "headline": "How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62"
              },
              {
                "id": 141153742,
                "url": "https://finnhub.io/api/news?id=837899412ca90fb440861401f61ce0c54a661cfb43a0e5c8b1ba038ae6be9f54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.",
                "category": "company",
                "datetime": 1786143956,
                "headline": "The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?"
              },
              {
                "id": 141150983,
                "url": "https://finnhub.io/api/news?id=dd12bcdfe4ed22cf3954c88504072df39a69214fa699b7fae9f00c2150af3b44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.",
                "category": "company",
                "datetime": 1786127896,
                "headline": "The Two Divergent Paths Priced Into Eli Lilly Stock"
              },
              {
                "id": 141149509,
                "url": "https://finnhub.io/api/news?id=cb6b2b98a77941dd72bcb3969bd00728210af178185fe7c7f56494f38f7a7dd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.",
                "category": "company",
                "datetime": 1786120560,
                "headline": "Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling."
              },
              {
                "id": 141161482,
                "url": "https://finnhub.io/api/news?id=bbf2b8261b83dac136b6bc78ae135adae86846c01a75e1bcff7ed3f9208e2976",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $345 to $405.",
                "category": "company",
                "datetime": 1786118840,
                "headline": "Citigroup Maintains Neutral on Amgen, Raises Price Target to $405"
              },
              {
                "id": 141147601,
                "url": "https://finnhub.io/api/news?id=beb277439b1f40d08250b2ff930d2ba90f77a0fde2d7a7476c18f8aecadb7384",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991691/image_2192991691.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen stock update: Tezspire and Repatha sales are surging as 2026 revenue guidance rises. Click here to read more about AMGN.",
                "category": "company",
                "datetime": 1786099867,
                "headline": "Amgen: The Market Is Underestimating Its Next Growth Phase"
              },
              {
                "id": 141147443,
                "url": "https://finnhub.io/api/news?id=7c944ae0c70f664f292ef576e53d337aa80687bb4224586adfaa6ac54f202827",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/Jakarta---December-12-2023-Chubb-Limited.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Bill Baruch chose Amgen Inc. as his final trade, citing its strong Q2 results and raised guidance. Malcolm Ethridge recommended Chubb.",
                "category": "company",
                "datetime": 1786089922,
                "headline": "Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141136309,
                "url": "https://finnhub.io/api/news?id=8ace18b0090935d1d8bfaff6a720c00daf04f71f71ccb5ba332aa2a85453f63e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the dow jones stocks that are in motion on Thursday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1786034404,
                "headline": "Thursday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140062550,
                "url": "https://finnhub.io/api/news?id=001a7b76a49603ab2797f8d9618eb3c4c2783cb0a2b1b42506d670dbf5e07af6",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1786021260,
                "headline": "Chubb shares are trading higher after multiple analyst firms raised their respective price targets on the stock."
              },
              {
                "id": 141138991,
                "url": "https://finnhub.io/api/news?id=9db3102ab3d2d6fd124632798024314f1fd7e56c4d9299590da6d7a4c91cd93b",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Bernstein  analyst Courtney Breen   maintains Amgen (NASDAQ:AMGN) with a Market Perform and raises the price target from $335 to $345.",
                "category": "company",
                "datetime": 1786019595,
                "headline": "Bernstein Maintains Market Perform on Amgen, Raises Price Target to $345"
              },
              {
                "id": 141133265,
                "url": "https://finnhub.io/api/news?id=35d180cdef293f1728f91bc9a59b11ce3ec717a9454e408cc06a253e7fefb1d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Companies In The News Are: AMGN, ANET, WYNN< BKNG.",
                "category": "company",
                "datetime": 1786010040,
                "headline": "Company News for Aug 6, 2026"
              },
              {
                "id": 141127472,
                "url": "https://finnhub.io/api/news?id=bd017c0528ccfd00832c2c6031003ccc90d79b75683fe659e0c958176b5b9997",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Rapid growth across cardiovascular, bone and rare-disease medicines allowed Amgen to raise guidance despite abandoning an obesity candidate.",
                "category": "company",
                "datetime": 1785963255,
                "headline": "Amgen Stock Climbs as Drug Growth Outruns Obesity Setback"
              },
              {
                "id": 141129206,
                "url": "https://finnhub.io/api/news?id=ed08274aee703ae13c43c3612a74d55272f248eb8721feafb82439a38b81fddd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stocks were mostly higher again as Iran and Oman negotiated a shipping agreement for the Strait of Hormuz, but AI capex is still a big issue for investors.",
                "category": "company",
                "datetime": 1785960543,
                "headline": "Dow Makes More New Highs Despite AI Drag: Stock Market Today"
              },
              {
                "id": 141125708,
                "url": "https://finnhub.io/api/news?id=aa4f6192ff266b0744702ba5908008c62f3442b9eaf167e489de658fd393aa13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rises Wednesday with word on a Strait of Hormuz deal. AMD stock and SpaceX fall.",
                "category": "company",
                "datetime": 1785956200,
                "headline": "Stock Market Today: Dow Rises, Nasdaq Slides As Tech Stocks Come Under Pressure; Uber Dives (Live Coverage)"
              },
              {
                "id": 141121105,
                "url": "https://finnhub.io/api/news?id=a3c02fdab82ec37292ab8838306b16cb77615cde3ea467ff3a798250d5b04bfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.",
                "category": "company",
                "datetime": 1785950886,
                "headline": "Stock Market Today: Dow Rises After Surprise Jobs Data; AMD, SpaceX Plunge On Earnings (Live Coverage)"
              },
              {
                "id": 141124262,
                "url": "https://finnhub.io/api/news?id=9031f1d6c1cbb5a0879f848573a5b1a0717397b864134372089df97d38bcdeaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per...",
                "category": "company",
                "datetime": 1785950700,
                "headline": "Amgen gains after strong quarterly results and continued product momentum"
              },
              {
                "id": 141138992,
                "url": "https://finnhub.io/api/news?id=c6a233b7592357dc859fa3bcc3cf26e53644adb872ee937317dfcc491536506e",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "UBS  analyst Michael Yee   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $420 to $440.",
                "category": "company",
                "datetime": 1785948841,
                "headline": "UBS Maintains Buy on Amgen, Raises Price Target to $440"
              },
              {
                "id": 141123271,
                "url": "https://finnhub.io/api/news?id=41596b07c037fe81a6963035041969d9a5305c9b2c7c1ef2d76aaea6efc80395",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1785947701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 141126014,
                "url": "https://finnhub.io/api/news?id=4ca154ba64515bee5ba02348b2bcfc96c4b3f716d2aaef53bf1dd2abbbbb6145",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.",
                "category": "company",
                "datetime": 1785945929,
                "headline": "Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan"
              },
              {
                "id": 141124169,
                "url": "https://finnhub.io/api/news?id=72c45d59d23cf8a80168bb098a63031a9d5d3b7a5025fb2a8250cc243fa24256",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.",
                "category": "company",
                "datetime": 1785945300,
                "headline": "AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure"
              },
              {
                "id": 141138993,
                "url": "https://finnhub.io/api/news?id=5ce029908270c25ee5b853a49a98ac97b580b9e9fc29641c5e2b40be0336d6d5",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "TD Cowen  analyst Yaron Werber   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $420 to $452.",
                "category": "company",
                "datetime": 1785944814,
                "headline": "TD Cowen Maintains Buy on Amgen, Raises Price Target to $452"
              },
              {
                "id": 141127473,
                "url": "https://finnhub.io/api/news?id=d659bafbebc473c2eba18aaf88342c7ac134adec10d55d0a610babc65579a1d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures (ESU26 ) are up +0.33%, and September E-mini Nasdaq futures...",
                "category": "company",
                "datetime": 1785942895,
                "headline": "Stocks Supported by Stellar Earnings"
              },
              {
                "id": 141124702,
                "url": "https://finnhub.io/api/news?id=ee671628e2288f45a3cd64e0b81f502ff1d01c147d65d0d7fe573912b3b2dc26",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen Inc. Q2 beat lifts FY guidance despite LOE headwinds; see portfolio drivers, pipeline catalysts, and M&A limits—click to read the AMGN highlights now.",
                "category": "company",
                "datetime": 1785939677,
                "headline": "Amgen: First $10 Billion Quarter, More Growth Ahead"
              },
              {
                "id": 141124772,
                "url": "https://finnhub.io/api/news?id=1db0cc6302bebe93b61e5eb9d2a4357679405616901a47c4a140ddf7ad352f6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/05/Digital-Gold-Price-Stock-Market-Trading-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.",
                "category": "company",
                "datetime": 1785939260,
                "headline": "Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today"
              },
              {
                "id": 141127474,
                "url": "https://finnhub.io/api/news?id=b1a23323c2ae6de83d631221eb1f8607c73547babbffd216e60de3e30cfd0255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU26 ) are up +0.50%, and September E-mini Nasdaq futures...",
                "category": "company",
                "datetime": 1785939129,
                "headline": "Strong Earnings Push the S&P 500 to New Record High"
              },
              {
                "id": 141122570,
                "url": "https://finnhub.io/api/news?id=8a9aed862fe00626b74388d7bd0bfa8f3652bc96e8189f67de8571e5e82f2ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.",
                "category": "company",
                "datetime": 1785938400,
                "headline": "AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline"
              },
              {
                "id": 141124011,
                "url": "https://finnhub.io/api/news?id=9cab0c533f8218d62aa1d10c3648eae8810ba4fefd32987e06e9adc6703e8239",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $340 to $362.",
                "category": "company",
                "datetime": 1785938051,
                "headline": "Truist Securities Maintains Hold on Amgen, Raises Price Target to $362"
              },
              {
                "id": 141121237,
                "url": "https://finnhub.io/api/news?id=1af5d56d3e4256f76e28ace5da3e91bcb76143676752182ee549789b1e3ad3cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion",
                "category": "company",
                "datetime": 1785936152,
                "headline": "Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513"
              },
              {
                "id": 141124012,
                "url": "https://finnhub.io/api/news?id=6d9a1c5e018c573a8aa210a9e86ed6cabb1e8b8a5abccec1a18a55bca9cd1bcd",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Oppenheimer  analyst Jay Olson   maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $450.",
                "category": "company",
                "datetime": 1785935772,
                "headline": "Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $450"
              },
              {
                "id": 141123516,
                "url": "https://finnhub.io/api/news?id=cfee7151b70d50ca233c1489fd303d07bef85684961be61106e689e1e44ef48e",
                "image": "https://image.cnbcfm.com/api/v1/image/108321360-17812891372026-06-12t182423z_83870851_rc2fslai0haj_rtrmadp_0_spacex-ipo-california.jpeg?v=1783445235&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1785932128,
                "headline": "Stocks making the biggest moves midday: Alphabet, SpaceX, Shopify, Newmont, Insulet, AMD & more"
              },
              {
                "id": 141121180,
                "url": "https://finnhub.io/api/news?id=3311c2f00176979b9f5c5138869991dc277499b8c45df4143e6b66c3ea940584",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "8.30am: ADP jobs softens US private-sector hiring slowed to 44,000 jobs in July from 98,000 in June, missing the 65,000 forecast and pointing to cooling labour demand. The softer reading could give the Federal Reserve more scope to cut rates, weighing on Treasury yields and the dollar...",
                "category": "company",
                "datetime": 1785931800,
                "headline": "Dow Jones and S&P 500 set to notch new highs despite AMD and SpaceX falls"
              },
              {
                "id": 141124013,
                "url": "https://finnhub.io/api/news?id=b9c4dc12632b0e6c0e414802c970d59db087e1f8911fb92c24af4a5ff3dd4599",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Scotiabank  analyst Louise Chen   maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $385 to $450.",
                "category": "company",
                "datetime": 1785930341,
                "headline": "Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $450"
              },
              {
                "id": 141124014,
                "url": "https://finnhub.io/api/news?id=03d0f8e354f0e00f3002da573605cc554746f841fcdbf229c8c2b254ec685201",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "RBC Capital  analyst Luca Issi   maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $370 to $400.",
                "category": "company",
                "datetime": 1785929849,
                "headline": "RBC Capital Maintains Outperform on Amgen, Raises Price Target to $400"
              },
              {
                "id": 141124015,
                "url": "https://finnhub.io/api/news?id=377281015364ba70c8664642d00d7b5850f86bf77440598080b8edfba96792a5",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $390 to $400.",
                "category": "company",
                "datetime": 1785927204,
                "headline": "Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $400"
              },
              {
                "id": 141124016,
                "url": "https://finnhub.io/api/news?id=f78ebe8223754c6db5746a8e4f8dc679a293092a7c38dc69f811341269e2e979",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $450.",
                "category": "company",
                "datetime": 1785916565,
                "headline": "BMO Capital Maintains Outperform on Amgen, Raises Price Target to $450"
              },
              {
                "id": 141119257,
                "url": "https://finnhub.io/api/news?id=c78686d056d119c01052d5be3c5a7c135531134c085fa378985c867a2e7bd6fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "How Amgen’s latest earnings event sets the stage for investors Amgen (AMGN) just released its second quarter 2026 results, reporting revenue of US$10.05b and net income of US$2.38b, alongside updated full year guidance that gives investors fresh numbers to work with. For the first half of 2026, Amgen reported revenue of US$18.67b and net income of US$4.19b. Basic earnings per share from continuing operations were US$7.77, with diluted EPS at US$7.71 for the period. The company now expects...",
                "category": "company",
                "datetime": 1785913989,
                "headline": "Amgen (AMGN) Lifted 2026 Guidance, Is The Valuation Still Too Rich?"
              },
              {
                "id": 141118740,
                "url": "https://finnhub.io/api/news?id=111a0a2b361a172dfb954481e0d0d24d9c37fda067babd0a686376b92a128d53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.",
                "category": "company",
                "datetime": 1785907077,
                "headline": "Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive"
              },
              {
                "id": 141118745,
                "url": "https://finnhub.io/api/news?id=ce655cda9c2e639d9ab1576fbb4456f3b10ea7d59a09b37d0f15234e1347ee95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc (AMGN) delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year 2026 guidance.",
                "category": "company",
                "datetime": 1785906389,
                "headline": "Amgen Inc (AMGN) (Q2 2026) Earnings Call Highlights: Revenue Surges Past $10 Billion, Guidance ..."
              },
              {
                "id": 141118106,
                "url": "https://finnhub.io/api/news?id=4e56419d2bb0b7e08ab73d60c539e900e341095659f96a419184e4cc6f062356",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) has reported a major cybersecurity breach that exposed sensitive patient health information. At the same time, regulators are reviewing the clinical data supporting its rare inflammatory disease drug Tavneos, following the retraction of a pivotal publication. Together, the data breach and questions over Tavneos data raise regulatory, reputational, and operational risks for Amgen. Amgen is a large biopharmaceutical company with a broad portfolio of therapies, including...",
                "category": "company",
                "datetime": 1785899959,
                "headline": "Amgen (AMGN) Faces Patient Data Breach And Tavneos Review Risk"
              },
              {
                "id": 141117853,
                "url": "https://finnhub.io/api/news?id=9aad17195addf2454d90ca7b345b9e1bf919cb038b27fc6e87688c29bfea3e5a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Amgen Inc. (AMGN) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsCasey Capparelli - Executive Director of Investor RelationsRobert...",
                "category": "company",
                "datetime": 1785885598,
                "headline": "Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141116480,
                "url": "https://finnhub.io/api/news?id=e09c7897cd1e0dcc1295b74ec76d0e3ece25ddb15450fde60d7f96f9a8ee1864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1785882601,
                "headline": "Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates"
              },
              {
                "id": 141116481,
                "url": "https://finnhub.io/api/news?id=4a3de612b3bf042fb801bf0228564e24e85a0bd4a395dde83f3f9170136593ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen",
                "category": "company",
                "datetime": 1785881036,
                "headline": "Amgen Q2 Earnings Call Highlights"
              },
              {
                "id": 141116482,
                "url": "https://finnhub.io/api/news?id=7b8f80a6192dce4d82b7e838b66d2fb347a63b690f1d8f5c562b2dc9bec04db8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785878102,
                "headline": "Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates"
              },
              {
                "id": 141114922,
                "url": "https://finnhub.io/api/news?id=0d78418fab0f15300f9b253e39543b407d6e381f8c8fe524fdaaf94721286188",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.5% year on year to $10.05 billion. The company’s full-year revenue guidance of $38.8 billion at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $6.29 per share was 12% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785875693,
                "headline": "Amgen (NASDAQ:AMGN) Delivers Strong Q2 CY2026 Numbers, Guides for Strong Full-Year Sales"
              },
              {
                "id": 141114923,
                "url": "https://finnhub.io/api/news?id=20990e9593992b3343ade119d6e20055c916b936d3a3f685f45a6533c8fbf0f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen smashed Wall Street's second-quarter expectations late Tuesday, delivering double-digit sales growth for nearly two dozen products.",
                "category": "company",
                "datetime": 1785873702,
                "headline": "Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash"
              },
              {
                "id": 141114924,
                "url": "https://finnhub.io/api/news?id=0ec33806d92d1bd23378424205b39afa9aa25cdf4c285b53b8783c7bad7f4279",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.",
                "category": "company",
                "datetime": 1785873660,
                "headline": "AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS"
              },
              {
                "id": 141113194,
                "url": "https://finnhub.io/api/news?id=f10599f0ef3cd06f7fbc95d32baf0a3b0cf23711e77e0d07c6d5a8accb248244",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz",
                "category": "company",
                "datetime": 1785867005,
                "headline": "Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes"
              },
              {
                "id": 141124017,
                "url": "https://finnhub.io/api/news?id=dcce302f592aec3fbae62a55589ede1c59edfbbd799250579f53a8308de37055",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "-Conference Call ",
                "category": "company",
                "datetime": 1785864223,
                "headline": "Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3"
              },
              {
                "id": 141114246,
                "url": "https://finnhub.io/api/news?id=96dbdd8eaab90afa24ec2e7b0f79c9f086812f420ee594f6a270e3b57bbe1710",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "2026-08-04. The following slide deck was published by Amgen Inc.",
                "category": "company",
                "datetime": 1785863035,
                "headline": "Amgen Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141124018,
                "url": "https://finnhub.io/api/news?id=a7804b01bd61ccfc517cb314617be3f25a3066c4976fe991167a2dc34df9f6f9",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ: AMGN) today announced it will discontinue Future development of AMG 513. A Phase 1 study of AMG 513 in adults living with obesity will remain ongoing to follow enrolled participants through completion of",
                "category": "company",
                "datetime": 1785862788,
                "headline": "Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity"
              },
              {
                "id": 141110788,
                "url": "https://finnhub.io/api/news?id=30905f0760c72cb9500a521fd9bc31fde32949ac88ad843d045fab1c8fb20a6c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1785861604,
                "headline": "Tuesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141113433,
                "url": "https://finnhub.io/api/news?id=04576ca58975816aa2a19ca8c3259f336a17133729ba02f3b79baa03bf7bacab",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153544205/image_1153544205.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Dow Dogs look overvalued but analysts see 18%–55% gains by Aug 2027; only 21/30 have safer dividends.",
                "category": "company",
                "datetime": 1785859586,
                "headline": "Dog Days On The Dow: No Buys With Weak Watching"
              },
              {
                "id": 141124019,
                "url": "https://finnhub.io/api/news?id=1dc7253aeaaef7bce3d7a4f7c74ed72c3d657f320fbf33d0dd9bb5fd83a57be2",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) narrows FY2026 GAAP EPS guidance from $15.62-$17.10 to $15.80-$17.08 vs $15.44 analyst estimate..",
                "category": "company",
                "datetime": 1785859371,
                "headline": "Amgen Narrows FY2026 GAAP EPS Guidance from $15.62-$17.10 to $15.80-$17.08 vs $15.44 Est"
              },
              {
                "id": 141124020,
                "url": "https://finnhub.io/api/news?id=b562ee488eb58fb94a74baf84cb04325e04328d0968f45b898c35a997828a97a",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) raises FY2026 Adj EPS guidance from $21.70-$23.10 to $22.30-$23.50 vs $22.35 analyst estimate. Raises FY2026 sales outlook from $37.100 billion-$38.500 billion to $38.200 billion-$39.400 billion vs",
                "category": "company",
                "datetime": 1785859366,
                "headline": "Amgen Raises FY2026 Adj EPS Guidance from $21.70-$23.10 to $22.30-$23.50 vs $22.35 Est; Raises FY2026 Sales Guidance from $37.100B-$38.500B to $38.200B-$39.400B vs $37.741B Est"
              },
              {
                "id": 141124021,
                "url": "https://finnhub.io/api/news?id=85301eacafb9a6875107683e52b97786f6450936e96bf05d7cada6be5ff32d17",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) reported quarterly earnings of $6.29 per share which beat the analyst consensus estimate of $5.62 by 11.92 percent. This is a 4.49 percent increase over earnings of $6.02 per share from the same",
                "category": "company",
                "datetime": 1785859363,
                "headline": "Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate"
              },
              {
                "id": 141111745,
                "url": "https://finnhub.io/api/news?id=385df106a61cb992ae950724cde993e2d163b0d2f34bda4c38056210caf601df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "BMY vs. AMGN: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1785858003,
                "headline": "BMY or AMGN: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141111550,
                "url": "https://finnhub.io/api/news?id=de33b8a0123d2b292054ba1f29716341249c010c55f9d5ee0e321353a5057f28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125572/image_2212125572.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.",
                "category": "company",
                "datetime": 1785851748,
                "headline": "OPKO Health: Mazdutide And MDX-2201 Could Change Everything"
              },
              {
                "id": 141108562,
                "url": "https://finnhub.io/api/news?id=88b66be7bd860f55e240a7631865e85d9b36505cd601ac24f6bb407c3e9c1159",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora",
                "category": "company",
                "datetime": 1785844682,
                "headline": "Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal"
              },
              {
                "id": 141107729,
                "url": "https://finnhub.io/api/news?id=1fe3c37f53ccf0db023332a8151ccefc9ee18b306784609f54ca69c090d1e07c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Wall Street futures pointed moderately higher pre-bell Tuesday after software giant Palantir Technol",
                "category": "company",
                "datetime": 1785842283,
                "headline": "Palantir Technologies Earnings Buoy Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 141111134,
                "url": "https://finnhub.io/api/news?id=725ba0c1062cda02bb8298ed42e7e33ba336ee54bf2ead90eaff485f3abe69ee",
                "image": "https://image.cnbcfm.com/api/v1/image/108344189-17857940671785794065-47560627544-1080pnbcnews.jpg?v=1785794066&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "'Fast Money' trader Carter Worth talks the technicals on Amgen heading into earnings.",
                "category": "company",
                "datetime": 1785779880,
                "headline": "Chart Master: Setting up for Amgen earnings"
              },
              {
                "id": 141099051,
                "url": "https://finnhub.io/api/news?id=ad9d450feda6978d6c374b0689e9bc8e63f8464d5cc0bfbb4f8587674ef3c471",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rallies 600 points Monday as Trump calls off new U.S. strikes on Iran. Oil prices plunge.",
                "category": "company",
                "datetime": 1785776738,
                "headline": "Stock Market Today: Dow Jumps 600 Points On Trump Strikes Reversal; Oil Prices Plunge (Live Coverage)"
              },
              {
                "id": 141100877,
                "url": "https://finnhub.io/api/news?id=e7f353f20f97bf055f0cc435212038f4c95916e647d02d99ac9a33f6f23370b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen is investigating the extent of this breach, as preliminary findings reveal that it has exposed private patient and proprietary information.",
                "category": "company",
                "datetime": 1785776414,
                "headline": "Amgen contends with data breach, exposing patient information"
              },
              {
                "id": 141100145,
                "url": "https://finnhub.io/api/news?id=c3effdf47636ff5cbe8c243812847c1cb7215361a84c36afbba1e09ca9287946",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Monday.",
                "category": "company",
                "datetime": 1785775204,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 141102051,
                "url": "https://finnhub.io/api/news?id=33813d4c4e93b221d5ec6d8104e03d00754ed6275b17a81ed6aeb5781d59adec",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Earnings-Season.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.",
                "category": "company",
                "datetime": 1785771021,
                "headline": "SpaceX Could Swing $204 Billion After Earnings"
              },
              {
                "id": 141099031,
                "url": "https://finnhub.io/api/news?id=a6b84888998779c7993582c4a54112bb58a6635d06165e2ff50694220384895e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Glen Allen, VA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Kaléo today announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors. This agreement reflects Kaléo's innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the agreement were not disclosed. About",
                "category": "company",
                "datetime": 1785758400,
                "headline": "Kaléo Announces License Agreement with Amgen for Auto-Injector Technology"
              },
              {
                "id": 141099326,
                "url": "https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.",
                "category": "company",
                "datetime": 1785751531,
                "headline": "AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"
              },
              {
                "id": 141097878,
                "url": "https://finnhub.io/api/news?id=9f2de0229b2b4e6e200d2cc5d04a8b90a4958b58cedca556c1f5b1a8b34d5020",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.",
                "category": "company",
                "datetime": 1785738562,
                "headline": "Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 5,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.5,
            "source_article_count": 164,
            "discarded_article_count": 148
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.5,
        "grade": "較差",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(20%→6%)；跌縮量(近10日5日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 2599646.6666666665,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2285790,
              "avg_vol_20": 2520595,
              "avg_vol_30": 2599646.6666666665,
              "range_pct_10": 0.06005203825435942,
              "range_pct_20": 0.16207890532274255,
              "range_pct_30": 0.20044738656075953,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8792694904692177,
              "dist_to_20d_high": 0.019931546025840585,
              "down_shrink_days": 5,
              "breakout_level_20d": 447.029999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2995900285093339
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.0155893362549073,
              "turnoverUsdM": 1031.3081928,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.AMGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 420.4586,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4,
            "take_profit_price": 460.026,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.240332023508895,
          "stopLossPercent": 4.031178672509815,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.AMGN",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 8.8307,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.02
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 59.72
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2693
    },
    "kdj": {
      "d": 65.36,
      "j": 31.66,
      "k": 54.13,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 60.2
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 6986240,
      "recentSlope": -621336,
      "previousSlope": 996500
    },
    "rsi": 65.16,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 445.8756,
      "position": "SAR喺價上",
      "distancePct": 1.77,
      "previousTrend": "下降"
    },
    "ma50": 391.6026,
    "macd": {
      "macd": 13.824083312231608,
      "trend": "中性偏多",
      "signal": 15.307428431211541,
      "histogram": -1.4833451189799334
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 424.0831,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 41
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.96,
      "score": 4,
      "avgVolume": 2457157,
      "currentVolume": 2353940
    },
    "derived": {
      "ma20": 426.4135,
      "ma50": 391.6026,
      "prevClose": 429.88,
      "avgVolume10": 2262044,
      "avgVolume20": 2457157,
      "changePercent": 1.92,
      "avgVolumeForScore": 2457157
    },
    "ma_cross": {
      "ma20": 426.4135,
      "ma50": 391.6026,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 424.0085,
      "prevMa50": 389.7346,
      "spreadPct": 8.89,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 401.2924,
      "upper": 451.5346,
      "position": "上半部"
    },
    "rsi_short": 37.12,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.96
    }
  }
}

{
  "close": 438.12,
  "volume": 2353940,
  "changePercent": 1.92
}